Related Experiment Videos
[Clinical evaluation of cefpirome in pediatric field]
S Matsuoka1, Y Takahashi, Y Kuroda
1Department of Pediatrics, School of Medicine, Tokushima University.
Insights
Cefpirome (CPR), a novel cephalosporin antibiotic, demonstrated high efficacy in treating infectious diseases in pediatric patients. The drug showed an 88.9% overall efficacy rate with minimal adverse effects, indicating its potential therapeutic value.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Background:
- Antibiotic resistance necessitates the development of new antimicrobial agents.
- Cephalosporins are a class of broad-spectrum antibiotics with established efficacy.
- Cefpirome represents a synthetic cephalosporin with potential applications in treating bacterial infections.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Cefpirome (CPR) in pediatric patients with infectious diseases.
- To determine the optimal dosage and duration of CPR treatment in this population.
Main Methods:
- A total of 10 pediatric patients (5 boys, 5 girls) aged 1 month to 5 years received intravenous Cefpirome.
- Dosages ranged from 53-100 mg/kg/day for 4 to 10 days.
- Clinical efficacy was assessed in 9 patients, with adverse effects monitored throughout the treatment period.
Main Results:
- Cefpirome demonstrated significant clinical efficacy, with 2 patients showing excellent response, 6 good, and 1 fair.
- The overall efficacy rate was 88.9% among the evaluated patients.
- One patient experienced a slight elevation in serum GOT and GPT, with no other adverse events reported.
Conclusions:
- Cefpirome is a highly effective antibiotic for treating infectious diseases in pediatric patients.
- The drug is well-tolerated, with a favorable safety profile in the studied population.
- Cefpirome shows promise as a valuable therapeutic option for pediatric infectious diseases.
Abstract:
Cefpirome (CPR), a new synthetic cephalosporin antibiotic, was administered to 10 patients with infectious diseases. The patients included 5 boys and 5 girls from 1 month to 5 years of age. They were given the drug intravenously at dosages ranging 53-100 mg/kg/day for 4 to 10 days. Clinical efficacy was evaluated in 9 patients: excellent in 2 patients, good in 6 patients and fair in 1 patient. The overall efficacy rate was 88.9%. No adverse effects were observed except in one patient who showed a slight increase of serum GOT and GPT.